Stocks slipped on Monday as investors questioned whether the market was getting ahead of itself following five straight winning weeks. The Dow Jones Industrial Avershed 60 points, or 0.2%. The S&P 500 lost 0.7%. The Nasdaq Composite declined 1.1% as investors sold Big Technology shares, which have led the market’s gains this year. On a red day, one NASDAQ stock that was up over 10% was Mangoceuticals, Inc. (NASDAQ: MGRX).
Mangoceuticals, Inc. (NASDAQ: MGRX), also known as MangoRx, has been making significant strides that could indicate its readiness for a stock market rebound. The company’s recent initiatives and expansions collectively showcase a robust and forward-thinking approach.
Partnership with TRYBE Labs: MangoRx’s collaboration with TRYBE Labs for nationwide blood collection and testing services is a strategic move. This partnership is critical for expanding MangoRx’s product lines that require blood tests reviewed by physicians and leverages TRYBE Labs’ FDA-approved, minimally invasive at-home blood collection technology.
Expansion of Men’s Health Product Line: According to the American Hair Loss Association, by the age of 35 two-thirds of American men will experience some degree of increased hair loss, and by the age of 50, approximately 85 percent of men have significantly thinning hair. The process of male pattern baldness can begin before the age of 21 for approximately 25% percent of men. “As a healthcare provider, I offer my professional endorsement of this compounded oral dissolvable tablet as a valuable option for addressing hair loss concerns,” said Dr. Douglas Christianson, ND, advisory board member of MangoRx in a recent press release. “The meticulously formulated combination of Minoxidil, Finasteride, Biotin, and Vitamin D3 aligns with evidence-based approaches to hair restoration. This cutting-edge solution has demonstrated clinical efficacy in fostering hair regrowth and enhancing the overall health of the hair. It stands as a medically sound choice for individuals seeking to address hair loss. As per the press release, the introduction of ‘Grow,’ a compounded hair growth treatment, marks a significant expansion in MangoRx’s product portfolio. This product, which combines Minoxidil, Finasteride, Vitamin D3, and Biotin in chewable tablets, targets a substantial market, given the prevalence of hair loss concerns among men.
For the uninitiated, according to a recent report, the global hair growth treatment product market was valued at USD 581.5 million in 2022 and is projected to reach USD 956.67 million by 2031, growing at a CAGR of 5.7%. This market includes products like shampoos, conditioners, serums, and oils that support hair growth by reducing hair loss and improving overall hair health. Factors driving the market include rising awareness about personal care, improved living standards, expanding fashion industry, increasing instances of hair loss due to lifestyle changes and pollution, and the growth of the e-commerce industry.
TikTok and Instagram Influencer Initiative: MangoRx’s launch of a Social Media Influencer Initiative, featuring top influencers on TikTok and Instagram, is a testament to the company’s commitment to modern marketing strategies. This initiative, along with the partnership with Barstool Sports and influencer Glenny Balls, aims to increase brand visibility and engagement within the target market, particularly in the men’s health space.
Unique MangoRX Formulation/Product: MangoRx’s focus on developing innovative men’s health products is further exemplified by its performance boosting drug, ‘Mango.’ This prescription medication demonstrates MangoRx’s emphasis on unique and effective health solutions.
MangoRx’s strategic partnerships, product line expansion, innovative marketing initiatives, and unique product formulations collectively suggest a company that is actively growing and adapting to market needs. These factors could play a crucial role in MangoRx’s potential recovery and growth in the stock market.
Mangoceuticals, Inc. (MGRX) demonstrates significant upside potential based on its stock statistics and recent company developments. Monday’s day’s trading range ($0.5600 – $0.7749) and the wider 52-week range ($0.4200 – $4.3700) suggest a high potential for growth, reflecting past higher levels. The trading volume, though below average, indicates active interest. The narrow bid-ask spread points to a healthy, liquid market. Coupled with MangoRx’s strategic expansions, partnerships, and product launches in the expanding men’s health sector, these factors collectively hint at a promising outlook for the stock, indicating potential room for an upward trajectory in its price. As always conduct your own due diligence and follow traders vigilance.
Some of the other notable stocks under 5$ on Monday around 3:00 pm EST include: Plug Power Inc. (PLUG) stands out with a trading price of $4.795, up 5.62%, and a high trading volume of 36.50M compared to its average of 29.70M, and a market cap of $2.90B. Canopy Growth Corporation (CGC) is another notable player, trading at $0.7596, marking a significant increase of 22.91%, with a volume of 51.67M over its average of 49.95M, and a market cap of $629.77M. Bitfarms Ltd. (BITF) follows, priced at $1.735 with a 4.52% gain and a substantial volume of 59.54M against a 9.58M average, showing a market cap of $559.04M. Farfetch Limited (FTCH) is trading at $1.3052, up 1.97%, with a volume of 22.36M compared to its 16.49M average, and a market cap of $516.16M. Finally, Altimmune, Inc. (ALT) has seen a remarkable increase of 27.31%, trading at $4.545, with a volume of 47.77M significantly over its 2.87M average, and a market cap of $244.88M.
Disclaimer: FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. InvestorBrandMedia.com has been compensated five thousand dollars by a 3rd party Bullzeyemedia LLC for advertisement and content distribution services on MGRX from 12/04/2023 to 12/31/2023. We own zero shares of MGRX. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.